0001179110-13-010426.txt : 20130617 0001179110-13-010426.hdr.sgml : 20130617 20130617080227 ACCESSION NUMBER: 0001179110-13-010426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130614 FILED AS OF DATE: 20130617 DATE AS OF CHANGE: 20130617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNTA PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: 45 HARTWELL AVE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-274-8200 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bahcall Safi R CENTRAL INDEX KEY: 0001325719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 13915641 MAIL ADDRESS: STREET 1: C/O SYNTA PHARMACEUTICALS CORP. STREET 2: 45 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 edgar.xml FORM 4 - X0306 4 2013-06-14 0 0001157601 SYNTA PHARMACEUTICALS CORP SNTA 0001325719 Bahcall Safi R C/O SYNTA PHARMACEUTICALS CORP. 45 HARTWELL AVENUE LEXINGTON MA 02421 1 1 0 0 President and CEO Common Stock 2013-06-14 4 P 0 10000 4.055 A 2003135 D Common Stock 15000 I By Safi R. Bahcall Irrevocable Trust Common Stock 65000 I By Neta Bahcall 2012 Irrevocable Trust Common Stock 400000 I By Princeton GRAT The shares were purchased in multiple transactions at prices ranging from $4.04 to $4.06 per share. The price reported above is the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth above. The Reporting Person disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Brian Keane, Attorney-in-Fact 2013-06-17